MX2020005193A - Fusiones de anticuerpo anti-pd-l1 e il-7. - Google Patents

Fusiones de anticuerpo anti-pd-l1 e il-7.

Info

Publication number
MX2020005193A
MX2020005193A MX2020005193A MX2020005193A MX2020005193A MX 2020005193 A MX2020005193 A MX 2020005193A MX 2020005193 A MX2020005193 A MX 2020005193A MX 2020005193 A MX2020005193 A MX 2020005193A MX 2020005193 A MX2020005193 A MX 2020005193A
Authority
MX
Mexico
Prior art keywords
fusions
antibody
fusion
fragment
protein
Prior art date
Application number
MX2020005193A
Other languages
English (en)
Inventor
Lei Fang
Zhengyi Wang
Bingshi Guo
Feifei Cui
Haijuan Gu
Jingwu Zang
Original Assignee
I Mab Biopharma Us Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Us Ltd filed Critical I Mab Biopharma Us Ltd
Publication of MX2020005193A publication Critical patent/MX2020005193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se provee una molécula fusionada que tiene un inhibidor de PD-L1 fusionado con una proteína IL-7 humana o fragmento de la misma por medio de un enlazador peptídico. Las moléculas fusionadas exhiben efectos antitumorales sinérgicos.
MX2020005193A 2018-01-25 2019-01-25 Fusiones de anticuerpo anti-pd-l1 e il-7. MX2020005193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018074121 2018-01-25
PCT/CN2019/073264 WO2019144945A1 (en) 2018-01-25 2019-01-25 Anti-pd-l1 antibody and il-7 fusions

Publications (1)

Publication Number Publication Date
MX2020005193A true MX2020005193A (es) 2020-08-20

Family

ID=67395659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005193A MX2020005193A (es) 2018-01-25 2019-01-25 Fusiones de anticuerpo anti-pd-l1 e il-7.

Country Status (14)

Country Link
US (1) US11401331B2 (es)
EP (1) EP3568417A4 (es)
JP (2) JP7102670B2 (es)
KR (1) KR20200058322A (es)
CN (1) CN110352202A (es)
AU (2) AU2019203918B2 (es)
BR (1) BR112020010536A2 (es)
CA (1) CA3082975A1 (es)
EA (1) EA202091054A1 (es)
IL (1) IL274564A (es)
MX (1) MX2020005193A (es)
SG (1) SG11202005036RA (es)
WO (1) WO2019144945A1 (es)
ZA (1) ZA202002568B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230071889A1 (en) * 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN114080397A (zh) 2019-05-17 2022-02-22 Xencor股份有限公司 Il-7-fc融合蛋白
KR102400884B1 (ko) * 2019-11-15 2022-05-23 주식회사 제넥신 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
WO2021209402A2 (en) * 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugates
WO2022020637A1 (en) * 2020-07-22 2022-01-27 Nektar Therapeutics Il-7 receptor agonist composition and related methods and uses
AU2021402065A1 (en) 2020-12-17 2023-06-29 Ose Immunotherapeutics Bifunctional anti-pd1/il-7 molecules
WO2023281479A1 (en) * 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
CN117660358B (zh) * 2024-01-31 2024-05-14 青岛华赛伯曼医学细胞生物有限公司 表达分泌型融合蛋白的工程化免疫细胞及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
DK2336167T3 (da) 2001-03-14 2019-09-02 Dako Denmark As MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi
BRPI0519000A2 (pt) * 2004-12-09 2008-12-23 Merck Patent Gmbh variantes de il-7 com imunogenicidade reduzida
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
EP2356219A4 (en) 2008-10-08 2017-07-05 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
MX362513B (es) * 2010-03-23 2019-01-22 Intrexon Corp Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos.
DK3564258T3 (da) * 2012-09-13 2021-06-21 Bristol Myers Squibb Co Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
US20170239297A1 (en) * 2014-08-18 2017-08-24 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
CN107488229B (zh) 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
AU2017284632B2 (en) * 2016-06-13 2020-05-14 I-Mab Biopharma Co., Ltd. Anti-PD-L1 antibodies and uses thereof
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
AU2017281830B2 (en) * 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
KR20210093950A (ko) * 2018-11-16 2021-07-28 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 면역 관문 저해제의 조합으로 종양을 치료하는 방법

Also Published As

Publication number Publication date
EA202091054A1 (ru) 2020-12-24
US11401331B2 (en) 2022-08-02
EP3568417A4 (en) 2020-07-15
JP2021506748A (ja) 2021-02-22
SG11202005036RA (en) 2020-06-29
AU2020210258A1 (en) 2020-08-20
JP7102670B2 (ja) 2022-07-20
EP3568417A1 (en) 2019-11-20
CA3082975A1 (en) 2019-08-19
BR112020010536A2 (pt) 2020-12-01
JP2022101631A (ja) 2022-07-06
AU2019203918B2 (en) 2020-04-30
US20190352405A1 (en) 2019-11-21
ZA202002568B (en) 2021-06-30
IL274564A (en) 2020-06-30
KR20200058322A (ko) 2020-05-27
WO2019144945A1 (en) 2019-08-01
AU2019203918A1 (en) 2019-08-08
CN110352202A (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
MX2020005193A (es) Fusiones de anticuerpo anti-pd-l1 e il-7.
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
ZA202100390B (en) Fusion constructs and methods of using thereof
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
BR112018070183A2 (pt) neoantígenos e métodos de seu uso
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
MX2018008592A (es) Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos.
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EP4321171A3 (en) Sirp alpha-antibody fusion proteins
PE20210168A1 (es) INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
DOP2019000178A (es) Inmunoglobulinas y usos de estas
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
MX2021010531A (es) Proteina de fusion bifuncional y uso farmaceutico de la misma.
WO2017060322A3 (en) Ptefb-inhibitor-adc
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MY194084A (en) Interferon beta antibodies and uses thereof
ZA202003320B (en) Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies
SA521420953B1 (ar) بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1